SCA Pharmaceuticals Appoints Milton Boyer as CEO

SCA Pharmaceuticals of Little Rock.

SCA Pharmaceuticals of Little Rock, which makes sterile pharmaceuticals for hospital pharmacies and health care facilities throughout the country, announced that Milton Boyer has been appointed CEO.

Boyer, a pharmaceutical industry veteran, will succeed Dr. Gene Graves, SCA’s founder, who announced his retirement on Sept. 6. Boyer will also serve on the company’s board of directors.

The company said Boyer has served in technical, commercial and executive roles in the pharmaceutical industry for more than 25 years with a specific focus in contract manufacturing for both drug substance and sterile drug product. 

Boyer most recently worked as senior vice president of drug product manufacturing at AMRI of Albany, New York, a global contract research and manufacturing organization. He joined AMRI in 2014 after AMRI’s acquisition of Oso BioPharmaceuticals, where he was president, CEO and a member of the board of directors.

“I am excited to join SCA at an important phase of the company’s development,” Boyer said in a news release. “I look forward to building on the growth that the company has experienced over the past seven years and working with SCA’s talented team to continue providing the highest quality products and services to our customers. I appreciate the support and guidance provided by Dr. Graves in this transition and the opportunity to execute the company’s vision.”

In May, SCA announced plans to build a 90,000-SF manufacturing facility in Windsor, Connecticut. The company aims to create 360 new jobs there over the next four years. The company employs about 200 people in Little Rock.